VU University Medical Centre, Department of Medical Oncology, Amsterdam, The Netherlands
Cancer Pharmacology Lab, AIRC Start-Up Unit, University of Pisa
CNR-Nano, Institute of Nanoscience and Nanotechnology, Pisa, Italy
G. Li PhD, A. Cavazzoni PhD, E. Giovannetti MD, PhD, M. A. Barbera MD, G. Frega MD, G. Biasco MD, I. Garajová MD, PhD
Despite significant improvement in anticancer treatment options, many patients are resistant or develop secondary resistance to anticancer agents, highlighting the necessity for seeking novel predictive markers for drug resistance. Piling evidence has identified miRNAs as predictive markers for resistance/sensitivity to chemotherapy and anti-VEGF/anti-EGFR monoclonal antibody therapy in colorectal cancer patients. In this review, we summarise the current knowledge of the role of miRNAs as possible response predictors to current anticancer treatments for metastatic colorectal cancer patients.